Published in J Cell Biochem on June 01, 2014
Regulation of chondroitin-4-sulfotransferase (CHST11) expression by opposing effects of arylsulfatase B on BMP4 and Wnt9A. Biochim Biophys Acta (2014) 0.79
Glycosaminoglycan derivatives: promising candidates for the design of functional biomaterials. J Mater Sci Mater Med (2015) 0.75
Sulfated hyaluronan alters fibronectin matrix assembly and promotes osteogenic differentiation of human bone marrow stromal cells. Sci Rep (2016) 0.75
Osteoporosis: now and the future. Lancet (2011) 5.81
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest (2013) 2.48
The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol (2012) 2.48
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Immune responses to implants - a review of the implications for the design of immunomodulatory biomaterials. Biomaterials (2011) 1.75
Bone, sweet bone--osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol (2012) 1.73
Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res (2012) 1.58
Osteoporosis: an age-related and gender-specific disease--a mini-review. Gerontology (2008) 1.57
RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol (2002) 1.52
Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab (2003) 1.46
Estimation of an early meaningful time point of bone parameter changes in application to an osteoporotic rat model with in vivo microcomputed tomography measurements. Lab Anim (2012) 1.40
Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab (2004) 1.35
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun (2002) 1.35
Gorham-Stout disease--stabilization during bisphosphonate treatment. J Bone Miner Res (2004) 1.29
Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity. Metabolism (2010) 1.25
Coating of titanium implants with collagen, RGD peptide and chondroitin sulfate. Biomaterials (2006) 1.25
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood (2003) 1.22
Development of a new calcium phosphate powder-binder system for the 3D printing of patient specific implants. J Mater Sci Mater Med (2007) 1.21
Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules (2006) 1.16
miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol (2011) 1.15
Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2. J Biol Chem (2008) 1.14
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res (2003) 1.14
Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med (2012) 1.12
The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant (2008) 1.11
Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation (2003) 1.09
WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res (2012) 1.08
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica (2013) 1.05
Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis (2005) 1.02
Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab (2004) 1.02
Osteoconductive modifications of Ti-implants in a goat defect model: characterization of bone growth with SR muCT and histology. Biomaterials (2005) 1.00
Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. J Bone Miner Res (2009) 1.00
Effect of RGD peptide coating of titanium implants on periimplant bone formation in the alveolar crest. An experimental pilot study in dogs. Clin Oral Implants Res (2002) 1.00
Coating of titanium implants with type-I collagen. J Orthop Res (2004) 1.00
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol (2007) 1.00
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun (2005) 0.99
Biological nano-functionalization of titanium-based biomaterial surfaces: a flexible toolbox. J R Soc Interface (2009) 0.99
Effect of immobilized bone morphogenic protein 2 coating of titanium implants on peri-implant bone formation. Clin Oral Implants Res (2005) 0.99
Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A (2006) 0.98
Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab (2011) 0.98
VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery (2002) 0.98
The role of osteoclast-associated receptor in osteoimmunology. J Immunol (2011) 0.97
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett (2009) 0.97
Pathophysiology of osteoporosis. Wien Med Wochenschr (2009) 0.95
Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res (2008) 0.95
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res (2013) 0.94
Release of metronidazole from electrospun poly(L-lactide-co-D/L-lactide) fibers for local periodontitis treatment. Dent Mater (2012) 0.94
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem (2011) 0.93
Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone (2009) 0.93
Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules (2009) 0.93
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol (2012) 0.93
Long-term cyclic strain downregulates endothelial Nox4. Antioxid Redox Signal (2009) 0.93
Quantification of dental erosion--a comparison of stylus profilometry and confocal laser scanning microscopy (CLSM). Dent Mater (2010) 0.93
Biomechanical comparison of different surface modifications for dental implants. Int J Oral Maxillofac Implants (2009) 0.92
Seizures associated with zoledronic acid for osteoporosis. J Clin Endocrinol Metab (2011) 0.92
Influence of extracellular matrix coatings on implant stability and osseointegration: an animal study. J Biomed Mater Res B Appl Biomater (2007) 0.92
The protease domain of procollagen C-proteinase (BMP1) lacks substrate selectivity, which is conferred by non-proteolytic domains. Biol Chem (2007) 0.91
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 0.91
Regenerative potential of glycosaminoglycans for skin and bone. J Mol Med (Berl) (2011) 0.91
Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol (2007) 0.91
In vivo effects of coating loaded and unloaded Ti implants with collagen, chondroitin sulfate, and hydroxyapatite in the sheep tibia. J Orthop Res (2007) 0.91
Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone (2011) 0.90
Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol (2003) 0.90
New aspects in the histological examination of polyethylene wear particles in failed total joint replacements. Acta Histochem (2002) 0.90
Skeletal and extraskeletal actions of denosumab. Endocrine (2012) 0.90
The effect of electrochemically simulated titanium cathodic corrosion products on ROS production and metabolic activity of osteoblasts and monocytes/macrophages. Biomaterials (2007) 0.90
Hydrostatic pressure stimulation of human mesenchymal stem cells seeded on collagen-based artificial extracellular matrices. J Biomech Eng (2010) 0.89
Artificial extracellular matrices composed of collagen I and sulfated hyaluronan with adsorbed transforming growth factor β1 promote collagen synthesis of human mesenchymal stromal cells. Acta Biomater (2011) 0.89
Effect of biological implant surface coatings on bone formation, applying collagen, proteoglycans, glycosaminoglycans and growth factors. J Mater Sci Mater Med (2007) 0.89
Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab (2012) 0.89
Response of human endothelial cells to oxidative stress on Ti6Al4V alloy. Biomaterials (2006) 0.89
Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine (Phila Pa 1976) (2009) 0.89
The osteogenic effect of electrosprayed nanoscale collagen/calcium phosphate coatings on titanium. Biomaterials (2009) 0.89
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res (2012) 0.89
Novel therapies in benign and malignant bone diseases. Pharmacol Ther (2012) 0.89
Graves' disease after treatment with alemtuzumab for multiple sclerosis. Hormones (Athens) (2015) 0.88
Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. J Bone Miner Res (2012) 0.88
Collageneous matrix coatings on titanium implants modified with decorin and chondroitin sulfate: characterization and influence on osteoblastic cells. J Biomed Mater Res A (2006) 0.88
Embroidered and surface modified polycaprolactone-co-lactide scaffolds as bone substitute: in vitro characterization. Ann Biomed Eng (2009) 0.88
Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem (2009) 0.88